NeoGenomics (NEO) Tops Q4 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/5/2026
- Dow claims record closing high, S&P 500 advances; chip selloff weighs on Nasdaq
- Broadcom results, guidance beat on soaring AI chip sales; stock slips after hours
- HSBC stays aggressive on stocks, asks what could turn it bearish
- SpaceX sets IPO price at $135 ahead of roadshow in break with Wall Street norms
- Crypto stocks sink as Bitcoin hits a 4-month low
- Wells Fargo Upgrades Oscar Health Inc (OSCR) to Equal Weight 'on Greater Confidence in Exchange Market Trajectory in 2026'
- Broadcom results, guidance beat on soaring AI chip sales; stock slips after hours
- Dow claims record closing high, S&P 500 advances; chip selloff weighs on Nasdaq
- LCI Industries names interim CEO as Jason Lippert retires
- Morgan Stanley lifts MU and SNDK targets, sees 2-3 years of tight memory supply
NeoGenomics Reports 122% Revenue Growth to $60.5 Million and 11% Reduction in Average Cost per Test in the Fourth Quarter of 2016
February 22, 2017 7:00 AM ESTFT. MYERS, FL -- (Marketwired) -- 02/22/17 -- NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, today reported its results for the fourth quarter and full year 2016.
Fourth Quarter 2016 Highlights:
140% increase in clinical genetic testing volume(1)122% increase in consolidated revenue to $60.5 million11% reduction in... More